产品中心
  Wechat

Wechat

  Contact Us

Address:

5th floor, Building 9, No.8 Shengmingyuan Road, Life Science Park, Zhongguancun, Changping District, Beijing, China

Email:

postmaster@abc.com

Tel:

+86-10-8492479489934358

Fax:

+86-10-84920734

Facilities


Generic Sites


Guangdong Sinotau


This facility came into operation in 2005, and was acquired by Sinotau Group in 2015. It is engaged in producing diabetes and cardiovascular products. The site has the flexibility to operate in the following dosage forms: Tablets, Capsules and Granules.

Guangdong site is equipped to deliver top quality products. The facility is operated by a highly qualified team of professionals with extensive experience. Both the equipment and the personnel guarantee the quality and efficiency of the manufacturing line. 


Due to the rapid development of Sinotau's activities, this facility has been expanded with a second unit built on 14,496 square meters of land. The corresponding GMP certification for this new unit has been already approved.


Sichuan Sinotau


 


The facility was established in 1994 and was acquired by Sinotau Group in 2014. This is a national GMP site engaged in R&D and the production of oral solutions. The facility is located in Pengzhou Pharmaceutical Industriy Park and the manufacturing unit is spread over an area of more than 30,000 square meters.


As a developer and also a manufacturer, this site maintains close collaboration with national and regional research institutions such as the Chinese Academy of Sciences, Sichuan Traditional Chinese Medicine Academy of Science, Sichuan University, among others.  


Radiopharmaceutical Sites

Sinotau will build 5 major radiopharmaceutical sites in China located in the North, East, South, Southwest and center region of the country. This network of facilities will integrate manufacturing and labeling of leading nuclear medicine products, training, R&D and international cooperation activities. All sites will be in line with cGMP standards.


Sites in East China (Jiangsu Province) and South China (Guangdong Province) are under construction. Network will cover 14 cities and 70% of radiopharmaceutical medicine users in the country.